ENTO Entero Therapeutics Inc.: Business Value to Revenue

Official company branding of Entero Therapeutics Inc. (ENTO)

Entero Therapeutics, Inc. (ENTO) faces geopolitical risks due to its reliance on Asian manufacturing; consequently, monitoring the chart on GURU.Markets reveals that the EV/Sales ratio is currently around 0.00. Outsourcing clinical trials and logistics to external partners optimizes the development of R&D projects, specifically the creation of current celiac disease therapies, which drives the company's qualitative growth within the gastrointestinal treatment segment.

Entero Therapeutics (ENTO): Company Value to Revenue from 11/23/2025 to 12/01/2025

Entero Therapeutics - analytical breakdowns and key metrics (ENTO)

- price and consensus price forecast:
- cash balance and cash flow data:
Fundamental company valuation:ENTO, Entero
Manufactured products of enterothera.com

An investment audit of Entero Therapeutics, Inc. (ENTO) requires an analysis of enterprise value (EV) to revenue, which allows for an assessment of the company's market price excluding debt load. The EV/Sales multiple trend reflects market expectations regarding the commercialization of gastrointestinal drugs, where any deviations from the chart signal a reassessment of clinical test potential and future sales volumes.